Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...
Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...
An effort two decades in the making, Vertex Pharmaceuticals Inc.’s suzetrigine gained U.S. FDA approval as the first drug targeting the NaV1.8 pain signal. Branded Journavx, the oral small molecule is ...
A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...
Vertex Pharmaceuticals could soon capture $10 billion in sales of non-opioid painkillers, an analyst said Friday as Vertex stock jumped.
The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which ...
After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...
Vertex Pharmaceuticals Up Nearly 6%, on Pace for Largest Percent Increase Since December 2023 — Data Talk Vertex Pharmaceuticals Incorporated (VRTX) is currently at $464.17, up $25.77 or 5.88% --Would ...
The drug represents a new pathway to treating people with pain due to surgeries or traumatic injuries, avoiding the addictive risks of opioids.
The U.S. Food and Drug Administration approved a new non-opioid pain medication developed by the Massachusetts-based company ...